Nexcella

Nexcella is a U.S.-based biotech advancing CAR-T cell therapy NXC-201 for the rare disease AL Amyloidosis, an area with significant unmet need and no FDA-approved CAR-T options. The company has generated promising early clinical data showing a 92% overall response rate and recently secured an $8 million grant from CIRM to support its ongoing NEXICART-2 U.S. trial. As a subsidiary of publicly-traded Immix Biopharma (IMMX), Nexcella leverages its parent's resources and expertise while aiming to address neurotoxicity challenges in CAR-T to improve accessibility for patients with immune-mediated diseases.

CAR-T cell therapy platform engineered with a focus on reducing neurotoxicity (ICANS) to improve safety and broaden treatment accessibility.

In AL Amyloidosis, NXC-201 faces competition from standard-of-care therapies like daratumumab, chemotherapy, and proteasome inhibitors, but no other CAR-T therapies are in clinical development for this indication. In the broader B-cell targeting space for autoimmune diseases, it would compete with other emerging cellular therapies and biologics.